<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645034</url>
  </required_header>
  <id_info>
    <org_study_id>A1481163</org_study_id>
    <nct_id>NCT00645034</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, 2-way Crossover Study to Investigate the Hemodynamic Effects of a Single Dose of Sildenafil (100mg) in Subjects With Benign Prostatic Hyperplasia Being Treated With Doxazosin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer's Upjohn has merged with Mylan to form Viatris Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of a single dose of sildenafil (100 mg) or placebo on blood&#xD;
      pressure and pulse rate in subjects taking doxazosin for benign prostatic hyperplasia (BPH).&#xD;
      To investigate the pharmacokinetics of doxazosin when co-administered with sildenafil 100 mg,&#xD;
      and to investigate the safety and toleration of sildenafil 100 mg when co-administered with&#xD;
      doxazosin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic parameters of blood pressure and pulse rate</measure>
    <time_frame>immediately predose, 15, 30, and 45 minutes and 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood samples for doxazosin pharmacokinetic parameters</measure>
    <time_frame>time 0 (pre-dose), and at 1, 2, 3, 4, 6, and 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toleration of simultaneously co-administering sildenafil and doxazosin.</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo by mouth as a single dose</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>sildenafil 100 mg by mouth as a single dose</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who weighed between 132 and 220 lb (60 and 100 kg) with benign prostatic&#xD;
             hyperplasia (BPH)&#xD;
&#xD;
          -  a total PSA (prostate specific antigen) measurement of less than or equal to 10 Âµg/L&#xD;
             within the 12 months prior to screening, were currently on doxazosin treatment for&#xD;
             BPH, had been treated with doxazosin for a minimum of 2 months prior to first dose of&#xD;
             study medication, and had received a minimum of 4 mg doxazosin once daily (from&#xD;
             doxazosin supplied for this study) for 2 weeks prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects with a recent history (i.e. within 6 months prior to screening) of stroke or&#xD;
             myocardial infarction&#xD;
&#xD;
          -  subjects with severe cardiovascular disorders such as unstable angina or severe&#xD;
             congestive heart failure&#xD;
&#xD;
          -  subjects with known hereditary degenerative retinal disorders, such as retinitis&#xD;
             pigmentosa&#xD;
&#xD;
          -  subjects with a supine systolic/diastolic blood pressure of &gt;170/100 mmHg or &lt;100/60&#xD;
             mmHg either at screening or at the pre-dose measurements&#xD;
&#xD;
          -  subjects receiving any other antihypertensive therapy other than doxazosin in the 3&#xD;
             weeks prior to the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Laguna Woods</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

